Advances on cardiovascular effects of GLP-lRAs / 中国药理学通报
Chinese Pharmacological Bulletin
; (12): 426-430, 2024.
Article
in Zh
| WPRIM
| ID: wpr-1013652
Responsible library:
WPRO
ABSTRACT
Glucagon-like peptide-1 ( GLP-1 ) is secreted by gut enteroendocrine cells. GLP-1 receptor agonists ( GLP-1 RAs) control glucose-related augmentation of insulin and suppress glu-cagon secretion. GLP-lRAs also inhibit gastric emptying, food intake and limit weight gain. In the past decade, significant progresses have been made in the investigation on the effects of GLP-1 RAs on cardiovascular system. The potential advantages of oral small-molecule GLP-1 RAs could improve the application of this class of drugs. This review highlights the multiple cardiovascular profiles of GLP-1 RAs in the treatment of cardiovascular diseases to provide new insights into cardiovascular benefits of GLP-1 RAs.
Full text:
1
Database:
WPRIM
Language:
Zh
Journal:
Chinese Pharmacological Bulletin
Year:
2024
Document type:
Article